Camp4 Therapeutics (CAMP) Liabilities and Shareholders Equity (2023 - 2026)
Camp4 Therapeutics (CAMP) reported Liabilities and Shareholders Equity of $105.5 million for Q1 2026, up 68.0% on a YoY basis from $62.8 million in Q1 2025, and down 10.48% sequentially from $117.8 million in Q4 2025.
Camp4 Therapeutics (CAMP) Liabilities and Shareholders Equity (2023 - 2026) Analysis & Trends
Camp4 Therapeutics (CAMP) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $105.5 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 68.0% year-over-year to $105.5 million; the trailing twelve-month figure through Mar 2026 stood at $360.9 million (up 122.19% YoY), and the FY2025 full-year result was $117.8 million, up 50.44% from the prior year.
- Liabilities and Shareholders Equity slipped to $105.5 million in Q1 2026, from $117.8 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $117.8 million in Q4 2025 to a low of $21.4 million in Q3 2024.
- A 4-year average of $72.3 million and a median of $70.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity soared 42.52% in 2024 and jumped 304.4% in 2025, its largest moves.
- Tracing CAMP's Liabilities and Shareholders Equity over 4 years: stood at $54.9 million in 2023, then soared by 42.52% to $78.3 million in 2024, then jumped by 50.44% to $117.8 million in 2025, then fell by 10.48% to $105.5 million in 2026.
- Business Quant data shows CAMP's Liabilities and Shareholders Equity at $105.5 million in Q1 2026, $117.8 million in Q4 2025, and $86.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Camp4 Therapeutics | 174.35 Mn | 174.35 Mn | - | 105.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105.46 Mn |
| Dec 31, 2025 | 117.81 Mn |
| Sep 30, 2025 | 86.40 Mn |
| Jun 30, 2025 | 51.28 Mn |
| Mar 31, 2025 | 62.77 Mn |
| Dec 31, 2024 | 78.31 Mn |
| Sep 30, 2024 | 21.36 Mn |
| Dec 31, 2023 | 54.95 Mn |